Hello, everyone, and welcome to the working week. We hope your weekend was refreshing. Now, though, the time has come to resume the usual routine of meetings and deadlines. To cope, we are, indeed, brewing the mandatory cup of stimulation - our flavor today is mocha fudge nut - and you are invited to join us. Meanwhile, here is the news of the world, which we often update throughout the morning. Let us know if you hear of something interesting yourself. And have a great day...
Japan Suspends Pfizer And Sanofi Vaccines Over Deaths (Bloomberg News)
Looking Over The Patent Cliff Again (The New York Times)
AstraZeneca Stops Making A Version Of Pulmicort (Associated Press)
FDA Rules On Social Media May Disappoint (Ad Age)
Biogen Wants To Build Blood Disorder Franchise (Reuters)
FDA Staff Question Dosing For Novartis Lung Drug (Reuters)
Merck Claims Organon Unit Sale Would Be Too Costly (Dutch News)
Australian Drug Theft Could Be An Inside Job (Sydney Morning Herald)
Generic Antidepressants Are Superior As First-Line Therapy (Pharma Times)
Canada To Vote On Generic Licensing Bill (Ottawa Citizen)
Indian Court Order For Barcodes Draws Protests (Economic Times)